Decade Capital’s Small-Cap Health Stock Picks Appear Primed For Growth

Page 1 of 2

Decade Capital Management LLC is a multinational investment management firm and a subsidiary of Israel Englander‘s Millennium Management LLC. The New York-based fund exclusively provides its services to a select group of private investment funds. The fund’s 13F filing with the U.S. Securities and Exchange Commission for the report period of March 31 revealed that the firm had a public equity portfolio value of $809.05 million. Considering the fund’s activities during the quarter, it’s clear that the analysts at Decade Capital were bullish on the market, seeing as the firm made 57 new purchases and increased its ownership position in 42 stocks. Its investment portfolio showed that it invested mainly in healthcare, which accounted for 46% of its portfolio. Being one of the hedge funds that we monitor, our experts considered some of its top small-cap healthcare picks, namely Insulet Corporation (NASDAQ:PODD), Molina Healthcare, Inc. (NYSE:MOH), and WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE:WX). This article looks into the performance of these three stocks.


The top small-cap picks of Decade Capital are notable to us given the fact that it’s investment firms like it that add great value to our small-cap strategy system, as they are heavily invested in the success of their small-cap picks and have poured considerable resources into identifying undervalued or under-the-radar companies to invest in. We have found that collectively, hedge funds’ top small-cap picks provide a great investment opportunity, with our strategy having returned over 142% since it was launched at the end of August 2012, beating the market by nearly 85 percentage points (see the details).

Follow Millennium Management Subsidiary's Decade Capital Management

The first of Decade Capital’s top small-cap picks that we are going to look into is Insulet Corporation (NASDAQ:PODD), in which the fund more than tripled its stake, increasing its position to 629,100 shares worth $20.98 million by March 31, from 178,991 shares held at the end of 2014. A keen look at the stock’s performance shows that the value of the stock has declined over the past six months, although its management remains more than optimistic about its prospects, signalling now may be a good time to get in at a discount, as Decade Capital has, and as company insiders have. May 28 saw the company’s CEO, Patrick Sullivan up his stake in Insulet Corporation (NASDAQ:PODD) by purchasing 20,000 shares at prices ranging from $27.74 to $28.08 on the open market. In terms of revenue, the company failed to meet expectations, with the underperformance being attributed to its delayed deliveries and a report issued by its leadership on reduced patient starts. Insulet, which focuses on making and distributing its OmniPod System used for insulin management, reported a loss of $0.21 in earnings per share in its most recent results, missing analysts’ consensus estimate of a loss of $0.10. A year-over-year comparison shows that the company’s revenue was down 11.6% for the quarter compared to the same quarter last year. A total of 25 hedge funds out of the more than 700 that we track were invested in the stock, having an aggregate of $382.78 million in investment value. Some of these hedge funds are David Greenspan‘s Slate Path Capital with 2.13 million shares, and Mariko Gordon’s Daruma Asset Management with 2.04 million shares.

Page 1 of 2